02291 SCIENTECH
- 23.550
- +0.050+0.21%
SCIENTECH News
Xintai Healthcare (02291) will pay a final dividend of $0.57 per share on September 30
Xintai Healthcare (02291) announced that the company will pay a final dividend per share on September 30, 2024...
心泰醫療：2023年度股東週年大會通告
心泰醫療：2023年度報告
LEPU ScienTech Medical Adopts New Standard for Financial Reporting; Replaces Auditor
LEPU ScienTech Medical Technology (Shanghai) (HKG:2291) will adopt the China Accounting Standards for Business Enterprises (CASBE) to prepare its financial statements beginning from the interim report
Xintai Medical (02291.HK) plans to appoint Lixin as a new auditor
Xintai Healthcare (02291.HK) issued an announcement. In view of the proposed adoption of Chinese accounting standards, in order to implement effective cost control and reduce overall operating expenses to better match the Group's future business development, on April 7, 2024, the company invited qualified accounting firms including PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) to tender for audit services for the year ended December 31, 2024. According to the audit tender results, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) was not selected. The Company Audit Committee was received from PricewaterhouseCoopers
Xintai Healthcare (02291.HK) plans to use Chinese corporate accounting standards to prepare financial statements and disclose relevant financial information
Xintai Healthcare (02291.HK) issued an announcement. In order to improve work efficiency and reduce the audit costs of preparing two financial statements in accordance with Chinese accounting standards and international financial reporting standards, on April 7, 2024, the board of directors reviewed and approved the preparation of the company's financial statements and disclosure of relevant financial information in accordance with Chinese corporate accounting standards starting from the interim report for the six months ending June 30, 2024, subject to approval by the company's shareholders at the recent annual shareholders' meeting to be held on May 23, 2024 to revise the company's articles of association.
SCIENTECH To Go Ex-Dividend On May 28th, 2024 With 0.62855 HKD Dividend Per Share
March 31st - $SCIENTECH(02291.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.62855 HKD dividend per share on September 30th, 2024. The ex-di
ScienTech Medical Turns Profitable in 2023
ScienTech Medical (HKG:2291) booked a profit attributable to owners of 151.5 million yuan for 2023, reversing a loss of 19.8 million yuan a year prior, according to a Thursday Hong Kong bourse filing.
Xintai Healthcare (02291) announced 2023 results, adjusted net profit increased 55.4% year-on-year to 173 million yuan, final interest of $0.57 per share
According to the Zhitong Finance App, Xintai Healthcare (02291) announced its 2023 results, with revenue of about 326 million yuan, an increase of 31.6% over the previous year. R&D expenses increased 14.3% year over year to 61.6 million yuan, and profit attributable to company owners was 151.5 million yuan, turning a loss into a profit year over year. Adjusted net profit increased 55.4% year over year to $173 million, with earnings of $0.44 per share and a final dividend of $0.57 per share (tax included). As of the date of this announcement, the group has a total of 22 marketed blocker and accessory products, 9 products under registration review and preparation for registration, and 24 products at different levels of development
SCIENTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
ScienTech Medical Forecasts Swing to Profit in 2023
ScienTech Medical (HKG:2291) is expecting the company to report an attributable profit to owners of between 140 million yuan and 160 million yuan, reversing the attributable loss of 19.8 million yuan
Xintai Medical (02291) Fa Yingxi expects annual net profit attributable to shareholders of about 140 million yuan to about 160 million yuan, turning a year-on-year loss into a profit
Xintai Medical (02291) announced that the Group expects to acquire the company for the year ending December 31, 2023...
SCIENTECH: INSIDE INFORMATION POSITIVE PROFIT ALERT
Xintai Healthcare (02291.HK) plans to hold a board meeting on March 28 to approve the annual results
Glonghui, March 15, 丨 Xintai Healthcare (02291.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
Xintai Healthcare (02291): Zhang Yuxin was reassigned as a non-executive director
Zhitong Finance App News, Xintai Healthcare (02291) announced that Zhang Yuxin has been transferred from an executive director to a non-executive director and will no longer serve as the company's deputy general manager and chief technical officer, effective March 1, 2024. Due to Zhang Yuxin's transfer, Zhang Yuxin is no longer the authorized representative of the company as stipulated in section 3.05 of the Listing Rules, and Gao Meiying, the company's co-company secretary and alternate authorized representative, has been appointed as the company's authorized representative as stipulated in section 3.05 of the Listing Rules, effective from March 1, 2024. In addition, Qiu Kejin was appointed as R&D director of the company's valve division, and Hu Jin was appointed
LEPU ScienTech Medical Units Invest 100 Million Yuan in Bank of Ningbo's Structured Deposit Products
Two units of LEPU ScienTech Medical Technology (Shanghai) (HKG:2291) subscribed for structured deposit products worth a total of 100 million yuan from Bank of Ningbo. Of this, units ScienTech Beijing
Xintai Medical (02291.HK) subscribes for 100 million yuan structured deposit products
Gelonghui, January 11, 丨 Xintai Healthcare (02291.HK) announced that on January 11, 2024, Xintai Beijing, a wholly-owned subsidiary of the company, signed a structured deposit product agreement I with Bank of Ningbo (Beijing Branch). Based on this, Xintai Beijing agreed to subscribe to a structured deposit product of RMB 30 million from Bank of Ningbo (Beijing Branch). On January 11, 2024, Shanghai Shape, a wholly-owned subsidiary of the company, signed a structured deposit product agreement II with Bank of Ningbo (Shanghai Branch). Based on this, Shanghai Shape agreed to subscribe to a structured deposit product of RMB 70 million from Bank of Ningbo (Shanghai Branch)
Medicine 2023: Winter is still around the corner, spring is getting stronger, innovative drugs “going overseas” welcome a big explosion, health insurance policies continue to warm | year-end inventory
“Science and Technology Innovation Board Daily”, December 27 (Reporter Xu Hong) Although the pharmaceutical industry is still cold in winter in 2023, the signs of “recovery” continue to increase. In particular, as the overall health insurance policy enters the optimization stage, not only will fundamental risks be further released, but it is also expected to greatly increase the certainty of growth of domestically produced innovative drugs.
SCIENTECH: 2023 INTERIM REPORT
China Grants Medical Device Registration for LEPU ScienTech Unit's Heart Occluder
China's medical products administration granted LEPU ScienTech Medical Technology (Shanghai) (HKG:2291) subsidiary Shanghai Shape Memory Alloy a medical device registration certificate for its foramen
Analysis
Price Target
No Data
